JAML immunotherapy targets recently activated tumor-infiltrating CD8+ T cells

Accepted/In Press date: 12 January 2023

e-pub ahead of print date: 25 January 2023

Published date: 28 February 2023

Additional Information: Funding Information: This work was funded by a combination of institutional, philanthropic, and corporate support. We thank C. Kim, D. Hinz, and C. Dillingham for their assistance with cell sorting (FACS Aria Fusion Cell Sorter; grant no. S10 RR027366); H. Simon for assistance with library preparation, next-generation sequencing using an Illumina HiSeq 2500 (NIH grant no. S10OD016262) and NovaSeq6000 (grant no. S10OD025052-01). This work was supported by the William K. Bowes, Jr. Foundation (P.V.) and the Whitaker Foundation (C.H.O.). The funders have no role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript. S.E. C.H.O. and P.V. conceived the work. S.E. A.W. H.S. Y.L. and M.M. performed experiments. S.E. C.R.-S. and V.C. analyzed data under the supervision of C.H.O. and P.V. M.E. performed the immunohistochemical analyses under the supervision of G.J.T. A.v.W. and S.J.C. analyzed the immunohistochemistry data with regard to the survival plots. S.E. wrote the first draft of the manuscript that was revised and edited by C.H.O. and P.V. The La Jolla Institute of Immunology has filed a patent “Methods for modulating an immune response to cancer or tumor cells” related to this work, and S.E. P.V. and C.H.O. are co-inventors on this patent. We support inclusive, diverse, and equitable conduct of research. Funding Information: This work was funded by a combination of institutional, philanthropic, and corporate support. We thank C. Kim, D. Hinz, and C. Dillingham for their assistance with cell sorting ( FACS Aria Fusion Cell Sorter; grant no. S10 RR027366 ); H. Simon for assistance with library preparation, next-generation sequencing using an Illumina HiSeq 2500 ( NIH grant no. S10OD016262 ) and NovaSeq6000 (grant no. S10OD025052-01 ). This work was supported by the William K. Bowes, Jr. Foundation (P.V.) and the Whitaker Foundation (C.H.O.) . The funders have no role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript. Publisher Copyright: © 2023 The Authors

Keywords: CP: Cancer, CP: Immunology, JAML, TRM cells, agonistic antibody, cancer immunotherapy, co-stimulatory molecule, tumor immunology

Local EPrints ID: 475927

URI: http://eprints.soton.ac.uk/id/eprint/475927

DOI: doi:10.1016/j.celrep.2023.112040

ISSN: 2211-1247

PURE UUID: 3511c1df-5997-4015-8f7f-e43a3100b4b9

Date deposited: 31 Mar 2023 16:33

Last modified: 05 Jun 2024 19:28